Tesla has been in the financial news for a variety of reasons over the last few months. There was a Tesla stock split, the company announced a recall, and the CEO Elon Musk is a constant source of buzz, a substantive Kardashian of science capable of space travel. The celebrity CEO of Tesla, Elon Musk, enjoys putting on a show and garnering interest for the company. Unfortunately, the Tesla stock often feels the impact of Musk's actions. However, Tesla just made some announcements that could change the landscape of artificial intelligence forever.

Intellegens has announced the latest release of its machine learning software, focused on key practical tasks to accelerate innovation for chemicals, materials, and manufacturing. Alchemite applies an Artificial Intelligence (AI) method developed at the University of Cambridge to optimise products and processes, reduce experimental workloads, and enable faster R&D progress. Ben Pellegrini, CEO at Intellegens comments: "We work closely with our chemical, materials, and manufacturing customers to focus our development work. Often, it's the small details that really make the software work in an industrial R&D environment. We're delighted that more organisations now benefit from Alchemite. Significant customer agreements so far this year have included a major steel manufacturer, world-leading speciality chemicals providers, additive manufacturing specialists, and a top global food producer."

GNW 9 million individuals are likely to be diagnosed with various types of cancer in the US. During the same year, around 0.6 million cancer-related deaths are anticipated to be reported in the aforementioned region. This, in turn, is expected to result in an increase of 70% in the global cancer burden, over the next two decades. Amidst the ever growing cancer burden, a number of strategies are being tested by researchers and industry players to help provide relief to the affected individuals. In recent years, artificial intelligence (AI) has emerged as a key enabler in improving the accuracy and speed of cancer diagnosis.

Ten years ago, if you bandied around the word Artificial Intelligence in a Kenyan newsroom, you would be branded an illusionist, today it is the buzzword. AI, machine learning and data processing are fast becoming essential in any newsroom that hopes to survive the digital revolution avalanche. In fact, job titles such as data scientist, data analyst, content strategist, content engineer and impact editors are fast gaining currency in media houses deemed digital journalism early adopters. Today, it is almost impossible to distinguish between an article authored by a machine and that written by a journalist, AI has enabled editors to figure out their audiences needs to granular levels and offer them articles that "speak to their souls". If the trend of automation of journalism catches on in the continent fast enough, in a few years it would be difficult to tell if the news anchor calling you "mpendwa msikilizaji" is a robot or human.

Desperate times call for desperate measures and no other big tech company is feeling the heat more than Meta Platforms Inc. A report published by Wall Street Journal last week revealed the strict new policy it has imposed on some employees asking them to either look for new positions somewhere else within the company or face termination. Meta has announced that it plans to cut costs by 10%. In the earnings released for the previous quarter, Meta's results looked grim. The company had lost close to 50% of its value by the second-quarter of this year.

Visiongain has published a new report entitled the Artificial Intelligence (AI) in Drug Discovery 2022-2032. It includes profiles of Artificial Intelligence (AI) in Drug Discovery and Forecasts Market Segment by Offering, (AI Software, AI Services) Market Segment by Technology, (Deep Learning, Supervised Learning, Reinforcement Learning, Unsupervised Learning, Other Technology) Market Segment by Applications, (Oncology, Infectious Diseases, Neurological Disorders, Metabolic Diseases, Cardiovascular Diseases, Other Applications) Market Segment by Type, (Target Identification, Molecule Screening, Drug Design and Drug Optimization, Preclinical and Clinical Testing) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country. The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032. AI makes use of the most recent developments in biology and computation to create cutting-edge drug discovery algorithms. AI has the potential to level the playing field in drug research, with to rapid increases in computing capacity and lower processing costs.

LONDON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Company's research report on the high energy lasers market, the emergence of artificial intelligence is gaining popularity among the high energy lasers industry trends. Many companies operating in the market are focused on developing AI-based products to get a competitive advantage. For instance, in April 2022, the US Navy successfully tested the Layered Laser Defense (LLD), a laser weapon designed and developed by Lockheed Martin, a US-based aerospace, arms, defense, information security, and technology company. This is the Layered Laser Defense (LLD). It can use a high-power laser to counter unmanned aerial systems and fast-attack boats, as well as track inbound air threats, support combat identification, and conduct battle damage assessments of engaged targets.

Air Recon DL's benefits extend to nearly all magnetic resonance imaging (MRI) clinical procedures. The platform covers all anatomies, enabling better image quality, shorter scan times and improved patient experience. GE Healthcare said in a news release that the solution's compatibility expands from 2D to 3D imaging sequences. This allows physicians to diagnose patients with an improved signal-to-noise ratio (SNR) and sharpness. Meanwhile, it said the 3D imaging provides for more clinical efficiency by eliminating the need for multiple 2D acquisitions.

Let a million monkeys clack on a million typewriters for a million years and, the adage goes, they'll reproduce the works of Shakespeare. Give infinite monkeys infinite time, and they still will not appreciate the bard's poetic turn-of-phrase, even if they can type out the words. The same holds true for artificial intelligence (AI), according to Michael Woolridge, professor of computer science at the University of Oxford. The issue, he said, is not the processing power, but rather a lack of experience. His perspective was published on July 25 in Intelligent Computing, a Science Partner Journal.

Dover, DE, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Metatron Inc. (OTC Pink: MRNJ), a mobile and web technology pioneer having developed over 2,000 apps on iTunes and Google Play, is pleased to announce that the Company has signed final agreement paperwork with Geek Labs Limited to complete Metatron's first acquisition of artificial intelligence technology. The acquisition was successfully negotiated by the two parties over the course of this past week. The acquisition will be a non-dilutive cash purchase and comes with immediate revenue-generating potential for Metatron. Furthermore, this technology acquisition is a wholly owned asset within the quickly growing $450 billion AI industry and can immediately be added to Metatron's corporate bottom line. CEO Joe Riehl commented: "One week ago we formally announced the formation of Metatron's Artificial Intelligence Division. Today we are announcing that we've inked a deal to complete our first AI tech acquisition. I want to send a crystal-clear message to our valued stakeholders that Metatron is entering a new chapter and taking fast steps to add impressive value for our investors. We already have our eye on a second acquisition and talks with the seller are at the midway point. Furthermore, our new AI division has begun planning projects with talented developers operating within the AI sector to build proprietary Metatron AI technology for use in specialty applications. Our new AI division also has begun performing due diligence on strategic AI patents that our team believes could be used in developing new technology and/or holding big tech companies accountable as more and more AI applications come into use."